Should Risk of Bias Be Assessed at the Outcome Level?

Дата публикации: 01-07-2026 00:00:00

To the Editor We read with great interest the individual patient data meta-analysis by Zaorsky et al investigating the optimal duration of androgen deprivation therapy in localized prostate cancer. We have some concerns about the risk of bias (RoB) assessment results. The authors stated, “Risk of bias assessments were conducted as outcome-specific for the primary and secondary end points.” However, the RoB appears to have been assessed at the trial level, rather than for individual outcome (eTable 8 in Supplement 1).

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Caution in Interpreting Survival After for Salvage Focal Therapy vs Salvage Radical Prostatectomy	0	8.37	01-07-2026
2	Caution in Interpreting Survival After for Salvage Focal Therapy vs Salvage Radical Prostatectomy	0	6.4	01-07-2026
3	Errors in Figures	0	12.94	01-07-2026
4	Prostate Cancer Mortality After Relabeling Low-Grade Prostate Cancer as Precancerous	0	9.66	01-07-2026
5	Caution in Interpreting Survival After for Salvage Focal Therapy vs Salvage Radical Prostatectomy—Reply	0	7.28	01-07-2026
6	Reassessing Treatment Outcomes Following Immune-Related Adverse Events—Reply	0	10.34	01-07-2026
7	Treatment Delays in Early Age–Onset Colorectal Cancer	0	8.3	01-07-2026
8	Circulating Tumor DNA in Early Breast Cancer	0	9.02	01-07-2026
9	PFS in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review	0	8.34	16-07-2026
10	Error in Byline	0	12.93	01-07-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 8.24. Источник: jamanetwork.com.